Ann: Anteo Technologies Signs Collaboration with Sona Nanotech, page-22

Hi Smilez, 

Just my 2c, as I’ve been thinking about this as well.  I think it comes down to supply/demand with an emphasis on demand.  As others have said, being greedy in establishing our first deal would be foolhardy in many respects, and whilst you don’t want to de-value the product, rewarding an early adopter willing to work with us and sign a long-term deal would be my idea of a solid first step.  IF A-Bind can be established as a standard, then we look at subsequent deals at premium pricing.  

Important to note, whilst the base tech remains the same, each applicae changes the formula (ie. cTnL assay, pregnancy tests, silicon/batteries, etc.).  Pricing of each unique formula for each unique deal should be considered.  It may be baselines for industry / test type / etc., but demand should be driving price unless I’m missing something.  In other words, pricing a 1 size fits all for unmodified A-Bind for different applications would be silly imho.

Anywho, just thinking out loud.  Happy Friday!

All IMHO, FWIW, DYOR, TFIF, blah blah blah...